Beijing Biostar Pharmaceuticals Co., Ltd. (HKG:2563)
Hong Kong
· Delayed Price · Currency is HKD 3.650
-0.010 (-0.27%)
At close: Mar 10, 2026
HKG:2563 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Net Income | -127.26 | -143.78 | -189.64 | -160.51 | -278.14 | -65.25 | Upgrade
|
| Depreciation & Amortization | 10.88 | 9.29 | 10.56 | 10.46 | 8.65 | 7.06 | Upgrade
|
| Other Amortization | 0.1 | 0.06 | 0.06 | 0.04 | 0.03 | 0.02 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | - | 0.08 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 0.2 | 0.2 | -9.1 | -10.85 | -22.39 | -7.36 | Upgrade
|
| Stock-Based Compensation | 9.06 | 9.06 | 44.4 | 80.74 | - | - | Upgrade
|
| Provision & Write-off of Bad Debts | 0.29 | 0.29 | -1.28 | 1.21 | 0.38 | -0.06 | Upgrade
|
| Other Operating Activities | -68.17 | -20.28 | -16.96 | -22.38 | 245.59 | 19.66 | Upgrade
|
| Change in Accounts Receivable | -12.49 | -12.49 | 25.22 | -6.9 | -20.92 | -3.5 | Upgrade
|
| Change in Inventory | -4.46 | -4.46 | 3.07 | -8.44 | -16.99 | -3.18 | Upgrade
|
| Change in Accounts Payable | 17.5 | 17.5 | 3.39 | 28.23 | 6.24 | -3.59 | Upgrade
|
| Change in Unearned Revenue | 47.17 | 47.17 | -0.71 | -1.53 | -1.3 | -2.94 | Upgrade
|
| Change in Other Net Operating Assets | -5.29 | -5.29 | -19.79 | 10.5 | - | - | Upgrade
|
| Operating Cash Flow | -132.47 | -102.72 | -150.78 | -79.44 | -78.77 | -59.14 | Upgrade
|
| Capital Expenditures | -15.46 | -40.81 | -27.84 | -31.86 | -11.06 | -4.81 | Upgrade
|
| Sale (Purchase) of Intangibles | - | - | - | -0.82 | - | - | Upgrade
|
| Investment in Securities | 54.63 | 79.38 | 145.98 | -114.11 | 121.93 | -435.53 | Upgrade
|
| Other Investing Activities | 15.62 | 15.62 | 13.14 | - | 17.57 | 19.77 | Upgrade
|
| Investing Cash Flow | 54.8 | 54.2 | 131.28 | -146.79 | 128.44 | -420.58 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 0.07 | - | - | Upgrade
|
| Total Debt Issued | - | - | - | 0.07 | - | - | Upgrade
|
| Short-Term Debt Repaid | - | - | -0.07 | - | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -1.22 | -1.01 | -1.13 | -1.08 | - | Upgrade
|
| Total Debt Repaid | -1.22 | -1.22 | -1.07 | -1.13 | -1.08 | - | Upgrade
|
| Net Debt Issued (Repaid) | -1.22 | -1.22 | -1.07 | -1.06 | -1.08 | - | Upgrade
|
| Issuance of Common Stock | 213.96 | 213.96 | - | - | 0.27 | 710.12 | Upgrade
|
| Other Financing Activities | -11.23 | -11.23 | -0.06 | 4.59 | - | -7.95 | Upgrade
|
| Financing Cash Flow | 201.52 | 201.52 | -1.13 | 3.53 | -0.81 | 702.18 | Upgrade
|
| Foreign Exchange Rate Adjustments | -8.36 | -1.37 | -1.39 | 14.38 | -4.9 | -1.79 | Upgrade
|
| Net Cash Flow | 115.5 | 151.63 | -22.02 | -208.31 | 43.96 | 220.67 | Upgrade
|
| Free Cash Flow | -147.92 | -143.52 | -178.62 | -111.3 | -89.83 | -63.95 | Upgrade
|
| Free Cash Flow Margin | -276.33% | -199.71% | -268.05% | -339.12% | -126.41% | - | Upgrade
|
| Free Cash Flow Per Share | -0.41 | -0.41 | -0.51 | -0.32 | -0.26 | - | Upgrade
|
| Cash Interest Paid | 0.06 | 0.06 | 0.06 | 0.07 | - | - | Upgrade
|
| Cash Income Tax Paid | 3.76 | - | - | - | 1.08 | 1.15 | Upgrade
|
| Levered Free Cash Flow | - | -169.76 | -99.06 | -46.54 | 23.12 | -43.67 | Upgrade
|
| Unlevered Free Cash Flow | - | -169.72 | -99.03 | -46.49 | 23.16 | -43.67 | Upgrade
|
| Change in Working Capital | 42.44 | 42.44 | 11.18 | 21.85 | -32.97 | -13.21 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.